comparemela.com

Page 8 - Base Genomics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rexnord, Regal Beloit merger headlines recent big deals in region

Rexnord, Regal Beloit merger headlines recent big deals in region Share Rexnord Corp. There has been plenty of merger and acquisition activity in Wisconsin in the past year, even after the COVID-19 pandemic introduced new uncertainty and slowed the pace of deals for several months.  One of the… Want to Read More? There has been plenty of merger and acquisition activity in Wisconsin in the past year, even after the COVID-19 pandemic introduced new uncertainty and slowed the pace of deals for several months.   One of the biggest deals of the past 12 months was just announced in mid-February as Milwaukee-based Rexnord Corp. will spin off its process and motion control business, which is the legacy portion of the company, and then merge it with Beloit-based Regal Beloit Corp.

Exact Sciences (EXAS) Q4 2020 Earnings Call Transcript

Exact Sciences (EXAS) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Exact Sciences (NASDAQ: EXAS) Thank you. Please, go ahead, sir. Erik Holznecht Investor Relations Thank you, Kathy, and thank all of you for joining us for the Exact Sciences fourth-quarter 2020 conference call. On the call, today are Kevin Conroy, the company s chairman and CEO; and Jeff Elliott, our chief financial officer. Exact Sciences issued a news release earlier this afternoon detailing our fourth-quarter financial results. This news release and today s presentation are available on our website at exactsciences.com.

Exact Sciences Falls in After-Hours Trading on Q4 Results

Exact Sciences Corporation (EXAS) Stock Forecasts

Exact Sciences Announces Fourth Quarter 2020 Results

Exact Sciences Announces Fourth Quarter 2020 Results News provided by Share this article Share this article MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic, said Kevin Conroy, chairman and CEO of Exact Sciences. We are a leader in cancer diagnostics because of our people, scientific platform, and market-leading Cologuard and Oncotype tests. We aim to extend this leadership throughout the cancer continuum and bring additional tests to patients to help improve cancer outcomes.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.